Evidence map›Paper›PMID 27234654›Full record

ArticleCarcinogenesis2016

Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).

Rosa M Xicola, Sneha Bontu, Brian J Doyle, Jamie Rawson, Pilar Garre, Esther Lee, Miguel de la Hoya, Xavier Bessa, Joan Clofent, Luis Bujanda and 16 more

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. mirSNPs as Potential Colorectal Cancer Biomarkers: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Systemic circulating microRNA landscape in Lynch syndrome.International journal of cancer · 2023
    Article
  6. Genetic Interaction ofPharmacogenomics and personalized medicine · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 19 institutions in 3 countries.

Rosa M XicolaDepartment of Medicine and Cancer Center, Yale University, New Haven, CT, USA.
Sneha BontuDepartment of Medicine and Cancer Center, Yale University, New Haven, CT, USA.
Brian J DoyleDepartment of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, IL, USA.
Jamie RawsonDepartment of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, IL, USA.
Pilar GarreLaboratorio de Oncología Molecular, Hospital Clinico San Carlos, IdISSC , Madrid, Spain.
Esther LeeDepartment of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, IL, USA.
Miguel de la HoyaLaboratorio de Oncología Molecular, Hospital Clinico San Carlos, IdISSC , Madrid, Spain.
Xavier BessaDepartment of Gastroenterology, Hospital del Mar, Barcelona, Catalonia, Spain.
Joan ClofentDepartment of Gastroenterology, Hospital de Sagunto, Sagunto, Valencia, Spain.
Luis BujandaDepartment of Gastroenterology, Hospital Donostia/Instituto Biodonostia, CIBERehd, Universidad del País Vasco (UPV/EHU), San Sebastian, Spain.
Francesc BalaguerDepartment of Gastroenterology, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
Sergi Castellví-BelDepartment of Gastroenterology, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
Cristina AlendaDepartment of Gastroenterology and Department of Pathology, Hospital General Universitario de Alicante, Alicante, Spain.
Rodrigo JoverDepartment of Gastroenterology and Department of Pathology, Hospital General Universitario de Alicante, Alicante, Spain.
Clara Ruiz-PonteFundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Grupo de Medicina Xenómica, IDIS, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERer), Santiago de Compostela, Galiza, Spain.
Sapna SyngalDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.
Montserrat AndreuDepartment of Gastroenterology, Hospital del Mar, Barcelona, Catalonia, Spain.
Angel CarracedoFundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Grupo de Medicina Xenómica, IDIS, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERer), Santiago de Compostela, Galiza, Spain.
Antoni CastellsDepartment of Gastroenterology, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
Polly A NewcombFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Noralane LindorDepartment of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.
John D PotterPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Epidemiology, University of Washington, Seattle, WA, USA Centre for Public Health Research, Wellington, New Zealand.
John A BaronDepartment of Biostatistics and Epidemiology, Dartmouth College, Lebanon, NH, USA.
Nathan A EllisDepartment of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
Trinidad CaldesLaboratorio de Oncología Molecular, Hospital Clinico San Carlos, IdISSC , Madrid, Spain xavier.llor@yale.edu trinidad.caldes@salud.madrid.org.
Xavier LLorDepartment of Medicine and Cancer Center, Yale University, New Haven, CT, USA xavier.llor@yale.edu.
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESUniversity of Illinois Chicago · USHospital Del Mar · ESHospital General Universitario de Alicante Doctor Balmis · ESYale Cancer Center · USBiogipuzkoa Health Research Institute · ESBrigham and Women's Hospital · USCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESDartmouth College · USFred Hutch Cancer Center · USHospital Clínic de Barcelona · ESHospital de Sagunto · ESMayo Clinic in Arizona · USServicio Gallego de Salud · ESUniversity of Arizona · USUniversity of Washington · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
USC Consortium:Colorectal Cancer Family RegistryU01CA074799 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAILE, ROBERT WILLIAM · 1997 to 2008
$20.4M
SEATTLE FAMILIAL COLORECTAL CANCER REGISTRYU01CA074794 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWCOMB, POLLY A · 1997 to 2007
$14.1M
ONTARIO REGISTRY FOR STUDIES OF FAMILIAL COLON CANCERU01CA074783 · NCI · CANCER CARE ONTARIO · PI GALLINGER, STEVEN · 1997 to 2008
$12.5M
Colon Cancer Family Registry CohortUM1CA167551 · NCI · STANFORD UNIVERSITY · PI HAILE, ROBERT WILLIAM, JENKINS, MARK A · 2013 to 2017
$11.3M
FAMILIAL COLORECTAL NEOPLASIA COLLABORATIVE GROUPU01CA074800 · NCI · MAYO CLINIC ROCHESTER · PI LINDOR, NORALANE MOREY · 1997 to 2007
$9.1M
The Colon Cancer Family Registry: USC ConsortiumU24CA074799 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAILE, ROBERT WILLIAM · 2008 to 2011
$7.6M
The Colon Cancer Family Registry: SeattleU24CA074794 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWCOMB, POLLY A · 2008 to 2011
$7.0M
AUSTRALASIAN COLORECTAL CANCER FAMILY REGISTRYU01CA097735 · NCI · UNIVERSITY OF MELBOURNE · PI HOPPER, JOHN L · 2002 to 2007
$6.9M
The Colon Cancer Family Registry: AustralasiaU24CA097735 · NCI · UNIVERSITY OF MELBOURNE · PI HOPPER, JOHN L · 2008 to 2011
$6.2M
HAWAII FAMILY REGISTRY OF COLON CANCERU01CA074806 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI LE MARCHAND, LOIC · 1997 to 2008
$6.1M
The Familial Colorectal Neoplasia Collaborative GroupU24CA074800 · NCI · MAYO CLINIC ROCHESTER · PI LINDOR, NORALANE MOREY, THIBODEAU, STEPHEN NORMAN · 2008 to 2011
$5.3M
NCATS NIH HHS UL1 TR001863NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA074799NCI NIH HHS U01 CA074800NCI NIH HHS U01 CA074806NCI NIH HHS U01 CA097735NCI NIH HHS U01 CA153060NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS U24 CA074799NCI NIH HHS U24 CA074800NCI NIH HHS U24 CA074806NCI NIH HHS U24 CA097735NCI NIH HHS UM1 CA167551
6 · The paper itself

Abstract

The purpose of this study was to identify novel colorectal cancer (CRC)-causing alleles in unexplained familial CRC cases. In order to do so, coding regions in five candidate genes (MGMT, AXIN2, CTNNB1, TGFBR1 and TGFBR2) were sequenced in 11 unrelated microsatellite-stable hereditary non-polyposis CRC (MSS HNPCC) cases. Selected genetic variants were genotyped in a discovery set of 27 MSS HNPCC cases and 85 controls. One genetic variant, rs67687202, in TGFBR1 emerged as significant (P = 0.002), and it was genotyped in a replication set of 87 additional MSS HNPCC-like cases and 338 controls where it was also significantly associated with MSS HNPCC cases (P = 0.041). In the combined genotype data, rs67687202 was associated with a moderate increase in CRC risk (OR = 1.68; 95% CI = 1.13-2.50; P = 0.010). We tested a highly correlated SNP rs868 in 723 non-familial CRC cases compared with 629 controls, and it was not significantly associated with CRC risk (P = 0.370). rs868 is contained in a let-7 miRNA binding site in the 3'UTR of TGFBR1, which might provide a functional basis for the association in MSS HNPCC. In luciferase assays, the risk-associated allele for rs868 was associated with half the luciferase expression in the presence of miRNA let-7b-5p compared with protective allele, suggesting more binding of let-7b-5p and less TGFBR1 expression. Thus, rs868 potentially is a CRC risk-causing allele. Our results support the concept that rs868 is associated with lower TGFBR1 expression thereby increasing CRC risk.

Indexed as

AdultAgedAllelesAxin Proteinbeta CateninBinding SitesColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairDNA Modification MethylasesDNA Repair EnzymesFemaleGene Expression Regulation, NeoplasticGenotypeHumansMaleMicrosatellite InstabilityAXIN2 protein, humanAxin Proteinbeta CateninCTNNB1 protein, humanDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IITGFBR1 protein, humanTumor Suppressor Proteins

Identifiers

PMID27234654
PMCPMC4967215
OpenAlexW2396275856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.